CP3 conducts innovative, policy-relevant research to improve the safety, effectiveness, and accessibility of medications. Our work addresses real-world challenges in prescribing, access, and pharmaceutical policy through rigorous methods and multidisciplinary collaboration.
Research
Drug Pricing and Cost
Drug pricing is an increasingly complex, prominent issue. Our faculty study and highlight the factors involved to provide clarity to patients and stakeholders. Research conducted examines trends in costs, the roles of payers and benefit managers, and drivers of pharmaceutical prices.
Explore our drug pricing and cost work.
Risk Prediction
At CP3, our research harnesses real-world data and advanced analytics to predict and prevent medication-related harm. We lead innovative projects that use machine learning algorithms embedded in electronic health records and public health systems to identify individuals at high risk of opioid overdose. By translating risk predictions into actionable insights, CP3 supports clinicians, health systems, and policymakers in delivering safer, more targeted care.
Explore our risk prediction projects.
Pharmacoepidemiology
CP3 conducts pharmacoepidemiologic research to evaluate how medications are used and their effects in real-world populations. Our work examines patterns of prescribing, medication safety, and the impact of pharmaceutical policies on health outcomes. By leveraging large datasets and rigorous methods, CP3 generates evidence to guide safer, more effective, and more equitable medication use across diverse healthcare settings.
Explore our pharmacoepidemiology projects.
Access to Care & Drug Shortages
Former CP3 Faculty Affiliate Dr. Utibe Essien coined the term "pharmacoequity" to describe a health system where all patients have access to the highest quality, evidence-based medical care. To advance the goal of achieving such a system, our faculty conduct research that informs ways to increase access to and cost burden from health services and medications and to decrease unfairness in health care and research. Read more about pharmacoequity in our JAMA Viewpoint.